| Literature DB >> 35148251 |
Yulan Lin1, Zhijian Hu1, Haridah Alias2, Li Ping Wong1,2.
Abstract
This study aimed to investigate nursing students' perspectives regarding the role of nurses as HPV vaccine advocates and their perception of barriers to advocacy. A cross-sectional study using a Web-based survey was sent out to all undergraduate nursing students enrolled at the Fujian Medical University, Fuzhou, China. A total of 1,041 students responded to the survey. In total, 58.0% of students expressed an intent to advocate HPV vaccines as a counselor and 56.4% as an HPV information provider in their future practice. However, 33.4% stated that they do not intend to be HPV vaccine advocates. Grade 1 students, students from homes with higher annual household incomes and those with a higher level of knowledge about HPV and HPV vaccination expressed higher intentions to advocate for HPV vaccines as a counselor. Students who have a higher level of knowledge about HPV and HPV vaccination and have received HPV vaccines reported a higher advocacy intent in the provision of HPV information. The main perceived barriers in HPV vaccine advocacy include inadequate training (87.1%) and insufficient HPV-related knowledge (84.8%); also, anxious patients may not feel comfortable with nurses discussing HPV vaccination (52.8%). Nurses are uniquely positioned to nurture patient HPV vaccine acceptance and maybe the key strategy to increase HPV vaccination coverage in China. Institutional support is needed to train nurses as HPV vaccine advocates and should focus on enhancing HPV-related knowledge while destigmatising the embarrassment around discussing HPV-related issues with patients.Entities:
Keywords: China; HPV; advocate; nursing student; vaccination
Mesh:
Substances:
Year: 2022 PMID: 35148251 PMCID: PMC8993049 DOI: 10.1080/21645515.2022.2030169
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452
Demographic characteristics and factors associated with advocacy intent (N = 1041)
| N (%) | HPV vaccine advocates through patient counseling | HPV vaccine advocates through provision of information/recommendation | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||
| Strongly intent/ Intent (n = 604) | OR (95%CI)a Strongly intent/ Intent vs. Not intent/ Strongly not intent | Strongly intent/Intent (n = 590) | OR (95%CI)a Strongly intent/ Intent vs. Not intent/ Strongly not intent | |||||
| Age | ||||||||
| <20 | 423 (40.6) | 242 (57.2) | .682 | 237 (56.0) | .863 | |||
| 20–21 | 473 (45.4) | 281 (59.4) | 268 (56.7) | |||||
| 22–24 | 145 (13.9) | 81 (55.9) | 85 (58.6) | |||||
| Gender | ||||||||
| Male | 150 (14.4) | 81 (54.0) | .285 | 90 (60.0) | .423 | |||
| Female | 891 (85.6) | 523 (58.7) | 500 (56.1) | |||||
| Ethnicity | ||||||||
| Han | 934 (89.7) | 549 (58.8) | .149 | 535 (57.3) | .258 | |||
| Others | 107 (10.3) | 55 (51.4) | 55 (51.4) | |||||
| Place of birth | ||||||||
| Urban | 319 (30.6) | 203 (63.6) | .017 | 1.31 (0.98–1.74) | 194 (60.8) | .078 | ||
| Rural | 722 (69.4) | 401 (55.5) | 1 | 396 (54.8) | ||||
| Geographic region of origin | ||||||||
| East China | 629 (60.4) | 382 (60.7) | .066 | 368 (58.5) | .165 | |||
| West China | 243 (23.3) | 127 (52.3) | 125 (51.4) | |||||
| Central China | 169 (16.2) | 95 (56.2) | 97 (57.4) | |||||
| Study grade | ||||||||
| Grade 1 | 290 (27.9) | 180 (62.1) | .030 | 1.55 (1.02–2.36)* | 176 (60.7) | .005 | 1.23 (0.81–1.88) | |
| Grade 2 | 281 (27.0) | 143 (50.9) | 0.94 (0.63–1.40) | 134 (47.7) | 0.69 (0.46–1.04) | |||
| Grade 3 | 295 (28.3) | 180 (61.0) | 1.22 (0.83–1.80) | 173 (58.6) | 0.97 (0.66–1.44) | |||
| Grade 4 | 175 (16.8) | 101 (57.7) | 1 | 107 (61.1) | 1 | |||
| Average annual family income (CNY¥)† | ||||||||
| <50000 | 529 (50.8) | 294 (55.6) | .010 | 1 | 292 (55.2) | .080 | ||
| 50000–120000 | 368 (35.4) | 210 (57.1) | 0.98 (0.75–1.30) | 204 (55.4) | ||||
| More than 120000 | 144 (13.8) | 100 (69.4) | 1.53 (1.01–2.31)* | 94 (65.3) | ||||
| Have taken HPV vaccine | ||||||||
| Yes | 78 (7.5) | 53 (67.9) | .074 | 55 (70.5) | .012 | 1.84 (1.10–3.06)* | ||
| No | 963 (92.5) | 551 (57.2) | 535 (55.6) | 1 | ||||
| Total knowledge score | ||||||||
| Score 0–11 | 513 (49.3) | 275 (53.6) | .005 | 1 | 266 (51.9) | .002 | 1 | |
| Score 12–20 | 528 (50.7) | 329 (62.3) | 1.46 (1.10–1.93)** | 324 (61.4) | 1.43 (1.08–1.88)* | |||
| Perceived susceptibility | ||||||||
| Agree | 826 (79.3) | 489 (59.2) | .141 | 481 (58.2) | .053 | |||
| Disagree | 216 (20.7) | 115 (53.5) | 109 (50.7) | |||||
| Perceived severity | ||||||||
| Agree | 968 (93.0) | 563 (58.2) | .806 | 553 (57.1) | .327 | |||
| Disagree | 73 (7.0) | 41 (56.2) | 37 (50.7) | |||||
| Perceived benefit of HPV vaccination | ||||||||
| Agree | 937 (90.0) | 555 (59.2) | .021 | 1.48 (0.97–2.25) | 542 (57.8) | .028 | 1.43 (0.94–2.19) | |
| Disagree | 104 (10.0) | 49 (47.1) | 1 | 48 (46.2) | 1 | |||
*p < .05, **p < .01.
aHosmer–Lemeshow test, chi-square: 9.036, p-value: 0.339; Nagelkerke R2: 0.041.
bHosmer–Lemeshow test, chi-square: 3.341, p-value: 0.648; Nagelkerke R2: 0.039.
†1 USD = 6.4 CNY.
Figure 1.Knowledge about HPV and HPV vaccination (N = 1041).
Figure 2.Perception of barriers in advocacy (N = 1041).
Factors associated with perceived barriers in advocacy (N = 1041)
| Total perceived barriers scores | ||||
|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | |||
| Score 6–14 | Score 15–24 | OR (95%CI)a | ||
| Demographic characteristics | ||||
| Age | ||||
| <20 | 157 (37.1) | 266 (62.9) | .011 | 1 |
| 20–21 | 163 (34.5) | 310 (65.5) | 1.16 (0.88–1.53) | |
| 22–24 | 34 (23.4) | 111 (76.6) | 2.02 (1.31–3.12)** | |
| Gender | ||||
| Male | 313 (35.1) | 578 (64.9) | .063 | |
| Female | 41 (27.3) | 109 (72.7) | ||
| Ethnicity | ||||
| Han | 322 (34.5) | 612 (65.5) | .389 | |
| Others | 32 (29.9) | 75 (70.1) | ||
| Place of birth | ||||
| Urban | 116 (36.4) | 203 (63.6) | .288 | |
| Rural | 238 (33.0) | 484 (67.0) | ||
| Geographic region of origin | ||||
| East China | 240 (38.2) | 389 (61.8) | .002 | 1 |
| West China | 71 (29.2) | 172 (70.8) | 1.43 (1.03–1.98)* | |
| Central China | 43 (25.4) | 126 (74.6) | 1.81 (1.22–2.67)** | |
| Study grade | ||||
| Grade 1 | 114 (39.3) | 176 (60.7) | .071 | |
| Grade 2 | 86 (30.6) | 195 (69.4) | ||
| Grade 3 | 103 (34.9) | 192 (65.1) | ||
| Grade 4 | 51 (29.1) | 124 (70.9) | ||
| Average monthly family income (CNY¥) | ||||
| <50000 | 158 (29.9) | 371 (70.1) | .016 | 1.33 (0.90–1.98) |
| 50000–120000 | 140 (38.0) | 228 (62.0) | 1.00 (0.67–1.49) | |
| More than 120000 | 56 (38.9 | 88 (61.1) | 1 | |
*p < .05, **p < .01.
aHosmer–Lemeshow test, chi-square: 6.945, p-value: 0.435; Nagelkerke R2: 0.038.
| A.1 | Age | ____________________years. |
|---|---|---|
| A.1 | Gender | [] Male |
| A.1 | Ethnicity | [] Han |
| A.1 | Place of birth | [] Urban |
| A.1 | Region of origin | [] East China |
| A.1 | Study grade | [] Grade 1 |
| A.1 | Annual monthly household income (CNY¥) | [] <50,000 CNY¥ |
| B.1 | Have you received HPV vaccination | [] Yes |
| | | True | False | Don’t know/Not sure |
| C.1.1 | HPV infection is common HPV | [] | [] | [] |
| C.1.2 | There are many types of HPV | [] | [] | [] |
| C.1.3 | HPV infection is most common among women aged 20 to 30 years | [] | [] | [] |
| C.1.4 | The annual pap smear test can detect cell change at the cervix | [] | [] | [] |
| C.1.5 | HPV infection is related to the development of cervical cancer HPV | [] | [] | [] |
| C.1.6 | HPV infection is sexually transmitted | [] | [] | [] |
| C.1.7 | Most people with HPV do not experience any symptoms | [] | [] | [] |
| C.1.8 | HPV cause genital warts HPV | [] | [] | [] |
| C.1.9 | HPV can cause oral cancer HPV | [] | [] | [] |
| C.1.10 | HPV can cause anal cancer | [] | [] | [] |
| C.1.11 | HPV infection can occur without symptoms HPV | [] | [] | [] |
| C.1.12 | HPV can infect both men and women HPV | [] | [] | [] |
| C.1.13 | HPV can be cured by antibiotics | [] | [] | [] |
| C.1.14 | Using condom will decrease the chance of getting HPV | [] | [] | [] |
| C.1.15 | There is a cure for HPV infection HPV | [] | [] | [] |
| | Following are questions regarding knowledge of HPV vaccine | True | False | Don’t know/Not sure |
| C.1.16 | HPV vaccine can prevent all types of HPV infection HPV | [] | [] | [] |
| C.1.17 | Someone who has had HPV vaccine cannot develop cervical cancer | [] | [] | [] |
| C.1.18 | It is best for young girls to receive HPV vaccination before their first sexual intercourse | [] | [] | [] |
| C.1.19 | HPV vaccine is only for people who are sexually active HPV | [] | [] | [] |
| C.1.20 | After receiving the HPV vaccine, women no longer have to be screened for cervical cancer | [] | [] | [] |
| D.1 | Perceived susceptibility to HPV and HPV-related diseases among women in general | |
| D.1.1 | Women, in general, have a high risk of contracting HPV in their lifetime | [] Agree |
| D.2 | Perceived severity of contracting HPV or having HPV-related diseases | |
| D.2.1 | Harms of HPV infection for women are severe | [] Agree |
| D.3 | Perceived benefit of HPV vaccination | |
| D.3.1 | HPV vaccines are highly effective in preventing HPV infection | [] Agree |
| E.1 | Providing my professional service as HPV vaccine advocate through patients counseling | [] Strongly not intent |
| E. 2 | Providing my professional service as HPV vaccine advocate through the provision of information/recommendation | [] Strongly not intent |
| F.1 | I believe nurses do not receive adequate training in advocating for HPV vaccination | [] Strongly agree |
| F.2 | I believe nurses do not have adequate knowledge about cervical cancer, HPV and HPV vaccination. | [] Strongly agree |
| F.3 | I don’t believe it is a nurse professional role to engage in advocating for HPV vaccination, it is better done by others in the healthcare team (eg. doctors) | [] Strongly agree |
| F.4 | I am worried patients may not be comfortable with nurses discussing with them about HPV vaccination | [] Strongly agree |
| F.5 | I feel uncomfortable engaging with patients in advocating for HPV vaccination | [] Strongly agree |
| F.6 | I am personally uncomfortable discussing with patients about HPV infection and HPV vaccination | [] Strongly agree |
| Odds ratio (OR) | 95% CI |
| |
|---|---|---|---|
| Demographic characteristics | |||
| Age | |||
| <20 | 1 | - | |
| 20–21 | 3.15 | 2.40–4.15 | <0.001 |
| 22–24 | 4.85 | 3.22–7.30 | <0.001 |
| Gender | |||
| Male | 1 | - | |
| Female | 2.32 | 1.61–3.33 | <0.001 |
| Ethnicity | |||
| Han | 1 | - | |
| Others | 0.71 | 0.47–1.06 | 0.093 |
| Place of birth | |||
| Urban | 1 | - | |
| Rural | 0.83 | 0.64–1.08 | 0.170 |
| Geographic region of origin | |||
| East China | 1 | - | |
| West China | 0.72 | 0.53–0.96 | 0.026 |
| Central China | 0.52 | 0.37–0.73 | <0.001 |
| Study grade | |||
| Grade 1 | 1 | - | |
| Grade 2 | 1.83 | 1.29–2.61 | 0.001 |
| Grade 3 | 5.31 | 3.73–7.58 | <0.001 |
| Grade 4 | 13.37 | 8.34–21.43 | <0.001 |
| Average monthly family income (CNY¥) | |||
| <50000 | 1 | - | |
| 50000–120000 | 1.39 | 1.06–1.81 | 0.17 |
| Above 120000 | 1.48 | 1.02–2.14 | 0.39 |
| Odds ratio (OR) | 95% CI |
| |
|---|---|---|---|
| Demographic characteristics | |||
| Age | |||
| <20 | 1 | ||
| 20–21 | 0.97 | 0.74–1.29 | 0.852 |
| 22–24 | 1.04 | 0.70–1.55 | 0.841 |
| Gender | |||
| Male | 1 | ||
| Female | 0.88 | 0.61–1.26 | 0.471 |
| Ethnicity | |||
| Han | 1 | ||
| Others | 1.27 | 0.84–1.92 | 0.259 |
| Place of birth | |||
| Urban | 1 | ||
| Rural | 1.25 | 0.94–1.66 | 0.130 |
| Geographic region of origin | |||
| East China | 1 | ||
| West China | 1.38 | 1.02–1.88 | 0.039 |
| Central China | 1.12 | 0.78–1.60 | 0.551 |
| Study grade | |||
| Grade 1 | 1 | ||
| Grade 2 | 1.55 | 1.10–2.20 | 0.013 |
| Grade 3 | 1.16 | 0.82–1.65 | 0.398 |
| Grade 4 | 1.17 | 0.78–1.75 | 0.460 |
| Average monthly family income (CNY¥) | |||
| <50000 | 1 | ||
| 50000–120000 | 0.99 | 0.75–1.30 | 0.927 |
| Above 120000 | 0.52 | 0.34–0.80 | 0.003 |